Company / Return on Assets (ROA)
Cullinan Therapeutics, Inc. Return on Assets (ROA) History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-26.9%
FY2024
5-year range
-31.6% / 19.8%
FY2020-FY2024
Trend
+14.9%
vs FY2023
Sector context
#121 of 213
Health Care
What the data says
At -26.9%, Cullinan Therapeutics, Inc.'s return on assets (roa) ranks #121 of 213 in the Health Care sector. Declined from 19.8% to -26.9% over the past 2 years.
Based on SEC 10-K filings.
-26.9% in FY2024 with a 3-year CAGR of -15.1%.
Declined from 19.8% to -26.9% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -15.1pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#121 of 213 in Health CareTop 57% of 213This company -26.9% Sector average -24.2%
▼
-11.4% below sector average
Key checks
Key Insights
- In FY2024, return on assets (roa) increased 14.9% year-over-year.
- Currently 2.8pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2022.
- Lowest return on assets (roa) in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -26.9% | +14.9% |
| FY2023 | -31.6% | -259.6% |
| FY2022 | 19.8% | +267.3% |
| FY2021 | -11.8% | +50.9% |
| FY2020 | -24.1% | - |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026